MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Danielle Brazel,1 Misako Nagasaka2,3 1Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, La Jolla, CA, USA; 2Department of Hematology/Oncology, University of California Irvine School of Medicine, Chao Family Cancer Center, Orange, CA, USA; 3Department of Medicine, St. Marianna...

Full description

Bibliographic Details
Main Authors: Brazel D, Nagasaka M
Format: Article
Language:English
Published: Dove Medical Press 2024-04-01
Series:Lung Cancer: Targets and Therapy
Subjects:
epidermal growth factor receptor (egfr) mutations
first line treatment
bispecific antibody
Online Access:https://www.dovepress.com/mariposa-can-amivantamab-and-lazertinib-replace-osimertinib-in-the-fro-peer-reviewed-fulltext-article-LCTT

Internet

https://www.dovepress.com/mariposa-can-amivantamab-and-lazertinib-replace-osimertinib-in-the-fro-peer-reviewed-fulltext-article-LCTT

Similar Items